Icatibant Hikma

Icatibant, the active ingredient in Icatibant Hikma, is a bradykinin B2 receptor antagonist presented as an injectable solution for intravenous use. It selectively blocks bradykinin‑mediated vasodilation and vascular permeability, providing rapid relief of swelling during acute hereditary angioedema attacks in patients with C1‑inhibitor deficiency.

GNH USA supplies Icatibant Hikma as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, specialty pharmacies, and clinical centres worldwide. The company adheres to stringent quality standards and provides regulatory support for import and distribution across multiple markets.

Icatibant is used to treat hereditary angioedema by targeting the bradykinin pathway.

Hereditary angioedema type I: Reduces the frequency and severity of swelling episodes by blocking bradykinin B2 receptors. Hereditary angioedema type II: Provides rapid symptom relief during acute attacks through inhibition of bradykinin‑mediated vascular leakage. Acute hereditary angioedema attacks: Delivers fast reduction of edema, improving patient comfort and airway safety.

Icatibant may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain or erythema - Nausea or vomiting - Headache or dizziness - Fatigue or mild fever

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity reaction - Sudden hypotension or cardiovascular collapse - Angioedema of the face, lips, or airway requiring emergency care

When prescribing icatibant, clinicians should consider several safety precautions.

Renal impairment: Monitor renal function and adjust therapy as needed. Hepatic impairment: Use with caution in patients with liver disease. Pregnancy: Safety not established; weigh potential benefits against risks. Concomitant ACE inhibitors: Increased risk of angioedema; evaluate necessity. Hypersensitivity: Discontinue immediately if allergic reaction occurs. Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medications that influence the bradykinin system or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: Additive bradykinin effect may precipitate angioedema. - Angiotensin receptor blockers: Similar risk of enhanced bradykinin activity. - Estrogen‑containing contraceptives: May increase frequency of hereditary angioedema attacks.

Moderate Interactions (Monitor Closely): - Diuretics: May potentiate hypotensive effects when combined with icatibant. - Beta‑blockers: Can mask tachycardia symptoms related to hypotension.